logo-loader
viewCellmid Limited

Cellmid gains new substantial shareholder as director increases his interest to 6.4%

US-based Dennis Eck recently purchased a $1 million parcel of shares and now holds more than 5.331 million.

Jars with increasing amounts of cash
Cellmid is an Australian life sciences accelerator

Cellmid Ltd (ASX:CDY) has a new substantial shareholder with US-based non-executive director Dennis Eck now holding a 6.4% interest in the life sciences company.

Eck has this month acquired more than 2.63 million shares valued at $1 million, bringing the total number held to more than 5.331 million.

This acquisition follows one last December in which he acquired 2.7 million shares for total value of $1.026 million.

 

Eck’s confidence in the company is shared by other directors who have made recent purchases in a variety of ways.

These include on-market trades and participation in the recent share placement and share purchase plan (SPP).

Managing director and CEO Maria Halasz acquired 263,157 shares valued at for $100,000 while non-executive directors Bruce Gordon and Dr Martin Cross have made purchases valued at $10,000 and $50,400 respectively.

READ: Cellmid’s study confirms effectiveness of lead antibody against rare chronic kidney disease

Cellmid is an Australian life sciences accelerator with lead programs in multiple disease indications.

The company holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) and FGF5 globally.  

Cellmid, through wholly-owned subsidiaries Lyramid, Kinera and Advangen, develops and markets innovative novel therapies and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases of the heart and hair loss.

Quick facts: Cellmid Limited

Price: 0.21 AUD

ASX:CDY
Market: ASX
Market Cap: $18.48 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cellmid Limited named herein, including the promotion by the Company of Cellmid Limited in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Cellmid Limited outlines key components for FY2020 growth strategy

Cellmid Limited (ASX:CDY) chief executive officer and managing director Maria Halasz updates Proactive Investors on the company’s key components for its FY2020 growth strategy, which includes an exciting new global product to assist ageing hair.  Cellmid is a listed company with health...

on 14/8/19

2 min read